Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Your Environment. Your Health.

Publication Detail

Title: Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures.

Authors: Galasko, Douglas R; Peskind, Elaine; Clark, Christopher M; Quinn, Joseph F; Ringman, John M; Jicha, Gregory A; Cotman, Carl; Cottrell, Barbara; Montine, Thomas J; Thomas, Ronald G; Aisen, Paul; Alzheimer’s Disease Cooperative Study

Published In Arch Neurol, (2012 Jul)

Abstract: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.Double-blind, placebo-controlled clinical trial.Academic medical centers.Subjects with mild to moderate Alzheimer disease.Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA); 400 mg of coenzyme Q 3 times/d; or placebo.Changes from baseline to 16 weeks in CSF biomarkers related to Alzheimer disease and oxidative stress, cognition (Mini-Mental State Examination), and function (Alzheimer's Disease Cooperative Study Activities of Daily Living Scale).Seventy-eight subjects were randomized; 66 provided serial CSF specimens adequate for biochemical analyses. Study drugs were well tolerated, but accelerated decline in Mini-Mental State Examination scores occurred in the E/C/ALA group, a potential safety concern. Changes in CSF Aβ42, tau, and P-tau(181) levels did not differ between the 3 groups. Cerebrospinal fluid F2-isoprostane levels, an oxidative stress biomarker, decreased on average by 19% from baseline to week 16 in the E/C/ALA group but were unchanged in the other groups.Antioxidants did not influence CSF biomarkers related to amyloid or tau pathology. Lowering of CSF F2-isoprostane levels in the E/C/ALA group suggests reduction of oxidative stress in the brain. However, this treatment raised the caution of faster cognitive decline, which would need careful assessment if longer-term clinical trials are conducted.clinicaltrials.gov Identifier: NCT00117403.

PubMed ID: 22431837 Exiting the NIEHS site

MeSH Terms: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease/cerebrospinal fluid*; Alzheimer Disease/drug therapy*; Amyloid beta-Peptides/cerebrospinal fluid; Antioxidants/administration & dosage*; Ascorbic Acid/administration & dosage; Biomarkers/cerebrospinal fluid*; Cholinesterase Inhibitors/therapeutic use; Dietary Supplements*; Double-Blind Method; F2-Isoprostanes/cerebrospinal fluid; Female; Follow-Up Studies; Humans; Male; Memantine/therapeutic use; Mental Status Schedule; Middle Aged; Peptide Fragments/cerebrospinal fluid; Retrospective Studies; Thioctic Acid/administration & dosage; Ubiquinone/administration & dosage; Ubiquinone/analogs & derivatives; alpha-Tocopherol/administration & dosage; tau Proteins/cerebrospinal fluid

Back
to Top